Tech Times on MSN
KRAS drug resistance has upstream cause: METTL13 enzyme fuels tumor protein overload
KRAS cancer treatment may have a new upstream target: the METTL13 enzyme that helps tumors overproduce KRAS protein and ...
A methylation mark on translation factor eEF1A selectively speeds decoding of rare, wobble-weak codons, boosting KRAS ...
A metagenomic study of acidic, CO2-rich groundwater reconstructed three thaumarchaeotal Group 1.1c genomes that lacked ...
Both low dose and high dose BB-301 continue to drive robust improvements in swallowing function for dysphagic Patients with Oculopharyngeal ...
March 25, 2020. A letter was issued by the Center for Food Safety and Applied Nutrition of the U.S. Food and Drug ...
This article explains the development and evaluation of GISMO and GISMO-mis, new constraint metrics that utilize mammalian ...
Cartesia Research demonstrates that Hierarchical Networks (H-Nets) learning dynamic tokenization from raw bytes achieve up to ...
Only about 5% of rare diseases have an approved therapy, and this is unlikely to change without novel development processes.
A new review of £53 million invested across 78 projects by the Cambridgeshire and Peterborough Combined Authority reveals an ...
Benitec Biopharma Inc. announced positive interim clinical results from the ongoing BB-301 Phase 1b/2a first-in-human study (NCT06185673) for Patients treated with high dose BB-301 and continued ...
A recent case report highlights a child with primary erythromelalgia driven by a novel SCN9A gene mutation who achieved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results